TROP2 Targeted Therapy: Module

CME

TROP-2–Targeted Therapy: Redefining the Therapeutic Landscape in HER2-Negative Breast Cancer

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: February 22, 2024

Expiration: February 21, 2025

Komal Jhaveri
Komal Jhaveri, MD, FACP

Activity

Progress
1 2
Course Completed

Introduction

In this module, Komal Jhaveri, MD, FACP, provides clinical insights into the current and emerging role of TROP-2‒directed antibody‒drug conjugates (ADCs) in the therapeutic landscape for patients with HER2-negative advanced breast cancer.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with breast cancer do you provide care for in a typical month?

A 54-year-old woman is diagnosed with de novo hormone receptor (HR)‒positive (estrogen receptor 90%, progesterone receptor 80%)/HER2 IHC 0 breast cancer and metastasis to the bone. She experienced disease progression in the liver after first-line therapy with letrozole and palbociclib for 3 years. She initiated second-line treatment with fulvestrant plus everolimus because next-generation sequencing showed no actionable alterations and genetic testing was negative for BRCA mutations. After 8 months, she experienced disease progression in the liver, and treatment with capecitabine was initiated. After 5 months, she experienced further progression in the bones and liver, and biopsy from the liver confirmed HR-positive (estrogen receptor 60%, progesterone receptor 10%)/HER2 IHC 0 breast cancer.

At this time, what would you recommend as the next best FDA-approved treatment option for this 54-year-old woman?